123 related articles for article (PubMed ID: 38287563)
1. Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2.
Krzyscik MA; Porębska N; Opaliński Ł; Otlewski J
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127657. PubMed ID: 38287563
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
3. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
[TBL] [Abstract][Full Text] [Related]
4. Modular self-assembly system for development of oligomeric, highly internalizing and potent cytotoxic conjugates targeting fibroblast growth factor receptors.
Poźniak M; Porębska N; Jastrzębski K; Krzyścik MA; Kucińska M; Zarzycka W; Barbach A; Zakrzewska M; Otlewski J; Miączyńska M; Opaliński Ł
J Biomed Sci; 2021 Oct; 28(1):69. PubMed ID: 34635096
[TBL] [Abstract][Full Text] [Related]
5. FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1.
Jendryczko K; Chudzian J; Skinder N; Opaliński Ł; Rzeszótko J; Wiedlocha A; Otlewski J; Szlachcic A
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33076489
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
[TBL] [Abstract][Full Text] [Related]
7. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
[TBL] [Abstract][Full Text] [Related]
8. Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1.
Nawrocka D; Krzyscik MA; Sluzalska KD; Otlewski J
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373291
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1).
Krzyscik MA; Zakrzewska M; Otlewski J
Mol Pharm; 2020 Jul; 17(7):2734-2748. PubMed ID: 32501706
[TBL] [Abstract][Full Text] [Related]
10. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
[TBL] [Abstract][Full Text] [Related]
12. Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.
Szlachcic A; Zakrzewska M; Lobocki M; Jakimowicz P; Otlewski J
Drug Des Devel Ther; 2016; 10():2547-60. PubMed ID: 27563235
[TBL] [Abstract][Full Text] [Related]
13. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
14. The Significance of Cell Surface N-Glycosylation for Internalization and Potency of Cytotoxic Conjugates Targeting Receptor Tyrosine Kinases.
Poźniak M; Żukowska D; Gędaj A; Krzyścik MA; Porębska N; Zakrzewska M; Otlewski J; Opaliński Ł
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955648
[TBL] [Abstract][Full Text] [Related]
15. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
[TBL] [Abstract][Full Text] [Related]
16. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
17. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
18. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
[TBL] [Abstract][Full Text] [Related]
19. Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers.
Porębska N; Knapik A; Poźniak M; Krzyścik MA; Zakrzewska M; Otlewski J; Opaliński Ł
Biomacromolecules; 2021 Dec; 22(12):5349-5362. PubMed ID: 34855396
[TBL] [Abstract][Full Text] [Related]
20. Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.
Damiani I; Castiglioni S; Sochaj-Gregorczyk A; Bonacina F; Colombo I; Rusconi V; Otlewski J; Corsini A; Bellosta S
Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34439990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
